10021290

Source:http://linkedlifedata.com/resource/pubmed/id/10021290

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0005740, umls-concept:C0006826, umls-concept:C0008838, umls-concept:C0009429, umls-concept:C0015133, umls-concept:C0556895, umls-concept:C1370419, umls-concept:C1512288, umls-concept:C2603343
pubmed:issue	2
pubmed:dateCreated	1999-3-11
pubmed:abstractText	The objectives of this study were to assess efficacy and toxicity of the combination of bleomycin, etoposide, and cisplatin (BEP) in this Phase II trial as first-line therapy for ovarian stromal malignancies.
pubmed:grant	http://linkedlifedata.com/resource/pubmed/grant/CA 27469, http://linkedlifedata.com/resource/pubmed/grant/CA 37517
pubmed:commentsCorrections	http://linkedlifedata.com/resource/pubmed/commentcorrection/10021290-10021289
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/0365304
pubmed:citationSubset	IM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/Bleomycin, http://linkedlifedata.com/resource/pubmed/chemical/Cisplatin, http://linkedlifedata.com/resource/pubmed/chemical/Etoposide
pubmed:status	MEDLINE
pubmed:month	Feb
pubmed:issn	0090-8258
pubmed:author	pubmed-author:BundyB NBN, pubmed-author:HomesleyH DHD, pubmed-author:HurteauJ AJA, pubmed-author:RothL MLM
pubmed:copyrightInfo	Copyright 1999 Academic Press.
pubmed:issnType	Print
pubmed:volume	72
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	131-7
pubmed:dateRevised	2007-11-14
pubmed:meshHeading	pubmed-meshheading:10021290-Adult, pubmed-meshheading:10021290-Age Factors, pubmed-meshheading:10021290-Aged, pubmed-meshheading:10021290-Aged, 80 and over, pubmed-meshheading:10021290-Antineoplastic Combined Chemotherapy Protocols, pubmed-meshheading:10021290-Bleomycin, pubmed-meshheading:10021290-Chemotherapy, Adjuvant, pubmed-meshheading:10021290-Cisplatin, pubmed-meshheading:10021290-Disease-Free Survival, pubmed-meshheading:10021290-Etoposide, pubmed-meshheading:10021290-Female, pubmed-meshheading:10021290-Granulosa Cell Tumor, pubmed-meshheading:10021290-Humans, pubmed-meshheading:10021290-Indiana, pubmed-meshheading:10021290-Middle Aged, pubmed-meshheading:10021290-Neoplasm Recurrence, Local, pubmed-meshheading:10021290-New York, pubmed-meshheading:10021290-North Carolina, pubmed-meshheading:10021290-Ovarian Neoplasms, pubmed-meshheading:10021290-Prospective Studies, pubmed-meshheading:10021290-Reoperation, pubmed-meshheading:10021290-Sex Cord-Gonadal Stromal Tumors, pubmed-meshheading:10021290-Treatment Outcome
pubmed:year	1999
pubmed:articleTitle	Bleomycin, etoposide, and cisplatin combination therapy of ovarian granulosa cell tumors and other stromal malignancies: A Gynecologic Oncology Group study.
pubmed:affiliation	Brookview Research Inc., Winston-Salem, North Carolina, 27103, USA.
pubmed:publicationType	Journal Article, Clinical Trial, Research Support, U.S. Gov't, P.H.S., Multicenter Study, Clinical Trial, Phase II